article = {AJSCR-2020-2-102}
title = {Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy (Hipec) for Recurrent Squamous Cell Carcinoma of the Pancreas}
journal = {American Journal of Surgical Case Reports}
year = {2020}
issn = {2674-5046}
doi = {http://dx.doi.org/10.31487/j.AJSCR.2020.02.02}
url = {https://www.sciencerepository.org/cytoreductive-surgery-combined_AJSCR-2020-2-102 
author = {A. Fotiadou ,A. Iliadis ,A. Kalakonas ,Antonios-Apostolos  Tentes,Ch. Hristakis ,D. Kyziridis ,}
keywords = {Squamous cell pancreatic carcinoma, peritoneal carcinomatosis, HIPEC}
abstract ={Background/Aims: Squamous cell carcinoma of the pancreas is a rare entity and its histogenesis is not
adequately understood. Surgical resection is the only potentially curative option. Recurrent local-regionally
pancreatic carcinomas are usually inoperable and are treated with palliative intent. The purpose of the study
is to present the treatment strategy of a recurrent squamous cell pancreatic carcinoma with peritoneal
carcinomatosis.
Case Report: A 49-year-old man with local-regional recurrent squamous cell pancreatic carcinoma
underwent complete (CC-0) cytoreductive surgery (CRS) and hyperthermic intraoperative intraperitoneal
chemotherapy (HIPEC). In a 6-month time he underwent secondary CRS+HIPEC for regional recurrence.
Despite treatment with adjuvant systemic chemotherapy the patient died 12 months after the initial CRS
with osseous metastases.
Conclusions: A reliable prognosis for recurrent squamous cell pancreatic carcinoma is impossible despite
complete cytoreduction in combination with HIPEC and systemic chemotherapy.}